<DOC>
	<DOCNO>NCT00006268</DOCNO>
	<brief_summary>RATIONALE : Immunotoxins locate tumor cell kill without harm normal cell . This may effective treatment malignant glioma . PURPOSE : Phase I/II trial study effectiveness immunotoxin therapy treat patient malignant glioma .</brief_summary>
	<brief_title>Immunotoxin Therapy Treating Patients With Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxic effect maximum tolerate dose ( MTD ) interstitial interleukin-13 PE38QQR immunotoxin patient malignant glioma . - Determine response rate , duration response , time response , overall survival , time progression patient treat regimen . - Determine toxic effect drug MTD patient . OUTLINE : This dose-escalation , multicenter study . Patients undergo stereotactic biopsy brain tumor follow CT guide stereotactic placement 2 intratumoral catheter day 0 . Patients histologically confirm malignant glioma receive interleukin-13 PE38QQR immunotoxin interstitially 96 hour begin day 1 . Patients residual enhance mass undergo repeat catheter placement day 56 receive second interstitial infusion begin day 57 absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos interleukin-13 PE38QQR immunotoxin maximum tolerate dose ( MTD ) determine . The MTD define dose 2 6 patient experience dose-limiting toxicity . Additional patient treat MTD . Patients follow every 8 week . PROJECTED ACCRUAL : A maximum 30 patient accrued phase I study within 6 month total 12-35 patient accrue phase II study within 10-12 month .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove malignant glioma ( grade 3 4 ) Anaplastic astrocytoma Glioblastoma multiforme Malignant mixed oligoastrocytoma Must undergone cranial radiotherapy tumor dose least 48 Gy least 12 week prior study Must undergone supratentorial brain tumor surgery biopsy Must radiographic evidence recurrent progressive supratentorial tumor compare prior study Must solid portion measure 1.05.0 cm maximum diameter Maximum 1 satellite lesion allow separated primary mass le 3 cm No tumor cross midline No leptomeningeal tumor dissemination No impend herniation spinal cord compression No uncontrolled seizure PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Hemoglobin least 10 g/dL Platelet count least 100,000/mm^3 Hepatic : PT PTT great upper limit normal ( ULN ) SGOT SGPT great 2.5 time ULN Bilirubin great 2.0 mg/dL Renal : Not specify Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 5 year except curatively treat carcinoma situ basal cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior intralesional chemotherapy malignant glioma At least 3 week since prior chemotherapy ( 6 week since prior nitrosoureas ) recover No concurrent chemotherapy Endocrine therapy : Concurrent corticosteroid allow , dose must remain stable taper study Radiotherapy : See Disease Characteristics No prior focal radiotherapy ( e.g. , form stereotactic radiotherapy brachytherapy ) malignant glioma Surgery : See Disease Characteristics Other : Recovered prior therapy No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2005</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>